Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) issued its earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02), FiscalAI reports.

Compass Therapeutics Price Performance

Shares of CMPX traded up $0.16 during mid-day trading on Friday, reaching $2.15. The company had a trading volume of 3,825,555 shares, compared to its average volume of 2,660,902. The company’s 50-day moving average is $2.09 and its 200-day moving average is $3.86. Compass Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.88. The company has a market capitalization of $387.19 million, a P/E ratio of -5.37 and a beta of 0.92.

Wall Street Analyst Weigh In

CMPX has been the topic of several recent analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 price target on the stock. Piper Sandler lifted their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.77.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPX. Invesco Ltd. grew its position in shares of Compass Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock worth $343,000 after buying an additional 3,245 shares during the period. XTX Topco Ltd raised its stake in shares of Compass Therapeutics by 582.2% in the 4th quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock valued at $621,000 after purchasing an additional 98,684 shares during the period. Ikarian Capital LLC bought a new stake in Compass Therapeutics in the 4th quarter valued at approximately $4,296,000. Virtus Investment Advisers LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $277,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Compass Therapeutics during the 4th quarter worth about $437,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.